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Abstract  
 The fibrotic diseases encompass a wide spectrum of entities including such multisystemic 
diseases as systemic sclerosis, nephrogenic systemic fibrosis and sclerodermatous graft versus 
host disease, as well as organ-specific disorders such as pulmonary, liver, and kidney fibrosis. 
Collectively, given the wide variety of affected organs, the chronic nature of the fibrotic 
processes, and the large number of individuals suffering their devastating effects, these diseases 
pose one of the most serious health problems in current medicine and a serious economic burden 
to society. Despite these considerations there is currently no accepted effective treatment. 
However, remarkable progress has been achieved in the elucidation of their pathogenesis 
including the identification of the critical role of myofibroblasts and the determination of 
molecular mechanisms that result in the transcriptional activation of the genes responsible for the 
fibrotic process. Here we review the origin of the myofibroblast and discuss the crucial 
regulatory pathways involving multiple growth factors and cytokines that participate in the 
pathogenesis of the fibrotic process. Potentially effective therapeutic strategies based upon this 
new information are considered in detail and the major challenges that remain and their possible 
solutions are presented. It is expected that translational efforts devoted to convert this new 
knowledge into novel and effective antifibrotic drugs will be forthcoming in the near future.  
 
Keywords:  Fibrotic Diseases, Myofibroblast, Fibrosis, Tyrosine Kinases, TGF-ß, Antifibrotic 
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The Problem 
Fibrotic diseases encompass a wide spectrum of entities including such multisystemic 
diseases as systemic sclerosis (SSc), sclerodermatous graft versus host disease, and nephrogenic 
systemic fibrosis, as well as organ-specific disorders such as pulmonary, liver, and kidney 
fibrosis (1-8). Although their etiology and causative mechanisms vary widely, these conditions 
share the common feature of elevated expression of genes encoding matrix proteins, and the 
resulting fibrosis disrupts the normal architecture of the affected organs, ultimately leading to 
their dysfunction and failure (9-11). Indeed, it is the persistent production of extracellular matrix 
(ECM) macromolecules by activated mesenchymal cells, known as myofibroblasts, that 
distinguishes controlled repair occurring during normal wound healing from the uncontrolled 
fibrosis that is the hallmark of fibrotic diseases.  
   Collectively, given the wide variety of affected organs, the chronic nature of the fibrotic 
processes, and the large number of individuals suffering their devastating effects, these diseases 
pose one of the most serious health problems in current medicine and represent an enormous 
challenge to health services, and a serious economic burden to society. It has been estimated that 
as much as 45% of the mortality in the Western developed countries is now caused by fibrotic 
diseases (11) and the mortality in underdeveloped or developing countries caused by these 
diseases is likely to be even much higher. Despite these considerations there is currently no 
accepted effective treatment.  However, recent identification of the critical role of the 
myofibroblast and elucidation of crucial regulatory pathways resulting in the transcriptional 
activation of the genes encoding collagens and other proteins responsible for the fibrotic process 
has been of substantial importance and has provided a sound basis for the development of novel 
and effective means of therapy. Unfortunately, the current lack of approved drugs for treatment 
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of these diseases indicates that recent knowledge has not yet been translated into effective 
therapies, however, it can be expected that this situation will be reversed in the near future. 
Origin and Critical Role of Activated Fibroblasts/Myofibroblasts in Fibrotic Tissues  
Although the causative agent or initiating event of the fibrotic disorders are quite diverse, and 
their pathogenesis is variable, a common feature in affected tissues is the presence of large 
numbers of activated fibroblasts or myofibroblasts. These cells display unique biological 
functions, including increased production of fibrillar type I and type III collagens, expression of 
α-smooth muscle actin (α-SMA), a molecular marker of activated myofibroblasts, and reduction 
in the expression of genes encoding ECM–degradative enzymes (12-15). Regardless of the 
etiological event, the accumulation of myofibroblasts in affected tissues and the uncontrolled 
persistence of their elevated biosynthetic functions are crucial determinants of the extent and rate 
of progression of the fibrotic diseases, and of their clinical course, response to therapy, 
prognosis, and mortality (9). 
The origins of myofibroblasts are diverse and may differ depending on the affected organ 
and the initiating event. There are four important sources of the myofibroblasts encountered in 
the fibrotic tissues as illustrated in Figure 1:  i) Proliferation and activation of tissue resident 
fibroblasts or perivascular and vascular adventitial fibroblasts in response to specific signals 
from infiltrating inflammatory cells resulting in activation of quiescent fibroblasts to a 
myofibroblast phenotype (16). ii) Recruitment of fibroblast precursor cells from bone marrow 
through local release of activated chemokines. These circulating bone marrow precursor cells are 
known as fibrocytes, a unique cell population expressing bone marrow cellular surface markers, 
such as CD34 protein, but capable of ECM production. These cells can migrate from the 
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bloodstream in response to specific chemokine gradients and localize in tissues undergoing 
pathological fibrogenesis (17-18). iii) Transdifferentiation of epithelial cells to myofibroblasts, a 
process known as epithelial to mesenchymal transition (EMT), which is induced by transforming 
growth factor β (TGF-β) and perhaps other polypeptides such as endothelin-1 (ET-1) or insulin 
growth factor (19-21). In EMT, epithelial cells lose their epithelial characteristics, including E-
cadherin expression and apical-basal polarity, and reorganize their cytoskeleton to acquire a 
motile behavior and the phenotype of myofibroblasts including the expression of α-SMA and 
fibroblast-specific proteins such as type I collagen. Although some recent studies employing 
genetic cell lineage tracing studies have raised controversy (22), numerous publications have 
described the occurrence of EMT in the course of renal, pulmonary, and liver fibrosis (21,23-25). 
iv) Another type of cellular transition similar to EMT, but in which endothelial cells undergo a 
mesenchymal transition (EndoMT) has emerged as a possible mechanism in pathological fibrosis 
(26,27). During EndoMT endothelial cells lose their specific endothelial cell markers, such as 
vascular endothelial cadherin (VE cadherin), and acquire a mesenchymal or myofibroblastic 
phenotype initiating expression of α-SMA, vimentin, and type I collagen. In addition, these cells 
also become motile and are capable of migrating into surrounding tissues. Similar to EMT, 
EndoMT can be induced by TGF-β (26,27). 
 Whereas investigations into the pathogenesis of fibrotic diseases have been ongoing for 
many decades, discoveries within the last ten years have more fully characterized the molecular 
complexity of the processes involved. Since its first identification in 1983 by Sporn and 
collaborators (28-30) it has been known that transforming growth factor-ß (TGF-β) a pleiotropic 
growth factor involved in the pathogenesis of numerous human diseases, plays a key role in 
fibrotic diseases by stimulating the production of various collagens and other ECM components 
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by activated mesenchymal cells (29,31-33). TGF-β also inhibits the synthesis of matrix 
degrading metalloproteinases and stimulates the production of tissue inhibitors of 
metalloproteinases (34). However, multiple recent findings have clearly identified numerous 
other cytokines including interleukins 4, 6, and 13 and several novel signaling pathways such as 
the Wnt, Hedgehog and Notch as potential participants. Several other important new insights 
have been made which have a critical bearing on therapeutic approaches for the fibrotic diseases. 
There is a growing realization that the clinical manifestations and the molecular pathogenesis of 
a given fibrotic disease are highly heterogeneous. As discussed above, besides the variety of 
causes, often poorly understood, which may be responsible for initiating the fibrotic response 
there is also increasing complexity at the cellular and molecular levels. Despite this 
heterogeneity, however, the final common result is the excessive production of ECM. Thus, the 
focus of this review will be on the cellular alterations and molecular pathways that play critical 
roles in the fibrotic response and to discuss potential strategies that may allow identification of 
potential therapeutic targets. 
Critical Molecular Pathways Participating in the Fibrotic Response 
Transforming Growth Factor Beta (TGF-β) 
The TGF-βs comprise three structurally similar proteins, TGF-β1, TGF-β2 and TGF-β3, 
with a wide and diverse spectrum of biological activities ranging from a role in embryonic 
development to regulation of the immune response and to the development of exaggerated 
fibrotic responses (35,36). Whereas deregulated TGF-β signaling occurs in essentially all fibrotic 
reactions, the specific mechanisms vary depending on the causative agent(s) and on the affected 
organ. TGF-β, initially produced as an inactive homodimeric peptide by numerous cell types, 
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including fibroblasts and macrophages, is secreted into the ECM as a large latent complex 
(Figure 2). The latent TGF-β complex consists of latent TGF-β binding protein covalently bound 
to a small latency complex formed by a homodimer of TGF-β which is bound to an RGD-
containing N-terminal latency associated binding peptide (37,38). TGF-β can undergo several 
alternative proteolytic or conformational activating events (39,40). Once activated TGF-β binds 
to a constitutively active serine/threonine transmembrane receptor kinase known as TGF-β 
receptor ll (TβRII). The intracellular transduction pathways following TGF-ß binding to its 
cognate receptors are quite complex and involve either the Smad pathways or non-Smad 
signaling pathways. The Smad pathways are often referred to as the canonical pathway whereas 
the non-Smad pathways are referred to as the non-canonical pathways. 
Canonical TGF-ß signaling pathways. 
In the classic or canonical pathway the ligand-bound TβRII recruits and phosphorylates a TGF-β 
receptor l (TβRI). The TβRl comprise a family of proteins also known as ALK proteins, two of 
which, ALK-1 and ALK-5, are involved in TGF-β signaling (41-43). ALK-5 is the most 
common TβRI and is phosphorylated by TβRII on three to five serine and threonine residues in a 
short 30 amino acid regulatory sequence. Signaling from the TβRI to the nucleus then occurs 
through the receptor activated RSmads, Smad2 or Smad3 which are phosphorylated by TβRl. 
The phosphorylated Smad2/Smad3 then bind to the co-Smad, Smad4, forming a complex that 
translocates across the nuclear membrane (44-48). In the nucleus the Smad complexes in 
association with co-activators and co-repressors and other transcription factors modulate the 
expression of target genes as illustrated in Figure 2. Fine tuning of TGF-β activity is achieved 
through a balance of positive and negative effector molecules. Of critical importance is the 
inhibitory Smad, Smad7, which inhibits TGF-β signaling through binding to TβRl receptor, 
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preventing recruitment and phosphorylation of RSmads and also facilitating TβRl degradation, 
leading to inhibition of RSmad activation (49). 
Non-Canonical TGF-ß signaling pathways. In addition to the Smad pathway, critical 
profibrotic signaling cascades independent of RSmads can be activated in a cell-specific and 
context-dependent manner and mediate important TGF-β effects (50,51). Of great importance 
with respect to the fibrotic effects of TGF-β is the finding that TGF-β stimulation leads to the 
activation of PI3K, which in turn activates two important profibrotic pathways: p21 activated 
kinase (PAK2)-Abelson kinase (Abl) and Akt-mTOR1 pathways. Downstream targets of c-Abl 
include known profibrotic mediators such as PKCδ/Fli-1, Egr, and Smad1 (52-55) as illustrated 
in Figure 2. Activated c-Abl is required for the activation of Smad1 and for the phosphorylation 
of protein kinase C-δ (PKC-δ), which in turn phosphorylates the transcription factor Fli-1 
reversing its inhibitory effect on collagen gene expression. Furthermore, recent studies have 
shown that the c-Abl-PKCδ pathway participates in the process of endothelial-mesenchymal 
transition (26). The activation of Smad1 downstream of TGF-β is of particular interest since total 
and phosphorylated Smad1 levels were significantly elevated in SSc skin biopsy samples and in 
cultured SSc fibroblasts (54). The Akt-mTOR pathway plays an important role in various cell 
processes including regulation of cell proliferation and metabolism as well as being involved in 
some epithelial/mesenchymal transitions (56). Another important non-Smad signaling pathway is 
through the activation of Jun N-terminal kinase (JNK) resulting in the activation of c-Jun, a 
critical profibrotic transcription factor (50,51). In addition to serine/threonine phosphorylation, 
TβRI can also be phosphorylated on tyrosine residues in response to TGF-β activation leading to 
activation of Erk1/2 MAPK, which can play an important role by regulating myofibroblast 
9 
 
formation as well as matrix synthesis (57-60). Other studies have shown that tyrosine 
phosphorylation of TβRII, triggers activation of p38 MAPK signaling (61,62). 
Connective tissue growth factor (CTGF/CCN2). 
CTGF, also known as CCN2, is another pleotropic growth factor that has recently 
emerged as an important mediator of normal and pathological tissue fibrotic responses (63,64) 
and it has been suggested to play a crucial role in SSc tissue fibrosis (65,66). In vitro studies in 
cultured fibroblasts have shown that the addition of recombinant CTGF or its overexpression 
induced fibrosis. Furthermore, in experimental mouse models, elevated levels of CTGF were 
associated with the development of fibrosis, and suppression of CTGF reduced bleomycin-
induced lung fibrosis (67).  TGF-β stimulates CTGF synthesis in fibroblasts, vascular smooth 
muscle cells and endothelial cells, and several studies have shown that CTGF acts as a 
downstream mediator to enhance the fibrogenic action of TGF-β (68).  Indeed, the CTGF 
produced by these cells in response to TGF-β stimulation in turn stimulates the synthesis of such 
ECM components as type I collagen and fibronectin in fibroblasts and very likely also in 
endothelial cells (63,64).  Significantly, Smad1 activation correlated with elevated CTGF protein 
and CTGF promoter activity and DNA binding assays demonstrated that Smad1 was a direct 
activator of the CTGF gene (54). Of considerable interest is the finding that imatinib mesylate, 
an inhibitor of c-Abl, blocked activation of the Smad1 pathway in TGF-β stimulated normal 
fibroblasts and abrogated stimulation of CTGF expression in SSc fibroblasts (54). These 
observations indicate that, at least in some circumstances, c-Abl is required for Smad-1 
activation. It should also be noted that CTGF expression can be independently stimulated 
through the RhoA/ROCK pathway (69) as illustrated in Figure 2. Currently, trials testing anti-
CTGF antibodies in interstitial pulmonary fibrosis (IPF) and liver fibrosis are ongoing. 
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Platelet derived growth factor 
 The platelet derived growth factor (PDGF) family consists of four different polypeptides, 
the original PDGF-A and PDGF-B, and the more recently described PDGF-C and PDGF-D. The 
biologically active PDGFs form disulphide-bonded dimers, such as PDGF-AA and PDGF-BB as 
well as a PDGF-AB heterodimers. The PDGFs bind and activate two structurally related tyrosine 
kinase receptors, PDGFRα and PDGFRβ. Ligand-induced receptor homo- or heterodimerization 
leads to autophosphorylation of specific tyrosine residues within the cytoplasmic domain. PDGF-
A activates PDGFRα, exclusively, whereas PDGF-B is capable of activating PDGFRα, 
PDGFRαβ and PDGFRβ. PDGF-AB can activate PDGFRα and PDGFRαβ (70-72). Receptor 
activation leads to  overlapping signal transduction pathways including PI3K, Ras-MAPK, Src 
family kinases and phospholipase Cγ (PLCγ) resulting in various cellular responses including 
proliferation, chemotaxis and actin reorganization as illustrated in Figure 3. Multiple reports 
have implicated PDGF in fibrotic reactions of several organs, including pulmonary, renal and 
hepatic fibrosis as well as in SSc (73). Fibroblasts are both major sources and targets for PDGF-
A since they express PDGFRα on their cell surface (74-76). Thus, PDGF-A/PDGFRα signaling 
loops can stimulate fibroblasts to synthesize ECM and release pro-fibrotic mediators. PDGF-B is 
primarily released by macrophages and hepatic stellate cells, with the latter ones also pointing to 
a major role of PDGF-B/PDGFRβ-signaling in liver fibrosis (77,78). Upon tissue injury PDGF 
signaling becomes activated to promote wound closure but PDGF signaling is tightly regulated 
and turned off as soon as the physiologic repair processes are completed (79). Failure to 
terminate activated PDGF signaling may lead to excessive scar formation and tissue fibrosis. 
Wnt-Signaling 
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While β-catenin has a structural role linking transmembrane cadherins to the actin 
cytoskleton, it also plays a critical role in canonical Wnt signaling.  In the absence of Wnt 
signals, β-catenin binds to and is phosphorylated by a complex consisting of adenomatosis 
polyposis coli (APC), axin, glycogen synthase kinase-3β (GSK-3β), and casein kinase which 
promotes subsequent degradation of β-catenin. Wnt proteins are secreted ligands that transmit 
their signal across the plasma membrane by interacting with Frizzled receptors and low-density 
lipoprotein receptor-related protein co-receptors (LRP5/6) as illustrated in Figure 3 (80). Wnt 
receptor binding disrupts the complex resulting in the stabilization of β-catenin which 
translocates to the nucleus, where it binds to T-cell factor/lymphoid enhancer-binding factor 
(Tcf/Lef) to induce target gene transcription such as axin-2 (81). Aberrant activation of the 
canonical Wnt signaling pathway has been implicated in a variety of pathological processes 
including pulmonary, renal, dermal and liver fibrosis, as well as, in scarring following 
myocardial infarction and fibrosis accompanying muscular dystrophy (82-86). Wnt signalling is 
tightly controlled by an array of negative regulators, among which, Dickkopf proteins (Dkk-1–4) 
have a key role. The best studied is Dkk-1, which functions as a natural secreted antagonist of 
Wnt signaling (87,88). 
Hedgehog Signaling 
 Mammalian orthologs of the Drosophila melanogaster  hedgehog (Hh) morphogen are 
highly hydrophobic secreted peptides and three different hedgehog proteins have been described, 
Sonic hedgehog (Shh), Indian hedgehog, and Desert hedgehog with Shh being the most 
important in the present context (89).  Patched (Ptc), a twelve-pass membrane protein binds Hh 
ligands, but in the absence of ligand, Ptc interacts with and inhibits Smoothened (Smo), a seven-
pass membrane protein (90). However, binding of Shh to Ptc1 induces conformational changes 
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that prevent Ptc1 from inhibiting Smo. The absence of Smo inhibition initiates a series of 
intracellular events resulting in stabilization of Gli family zinc finger transcription factors which 
in turn stimulate expression of Hh target genes (91) as illustrated in Figure 3. While Hh signaling 
is critical during embryonic development, inappropriate activation has been implicated in the 
pathogenesis of various diseases in adults, including a variety of malignancies (92-94). A recent 
study has shown that overexpression of Shh in cultured SSc fibroblasts activates the Hh pathway, 
with accumulation of the transcription factor Gli-2 and increased expression of Hh target genes 
(95). Furthermore, Shh potently stimulated the production of collagen and induced the 
differentiation of resting fibroblasts into myofibroblasts. Overexpression of Shh in the skin of 
mice was sufficient to induce fibrosis, and mice lacking one allele of the gene for the inhibitory 
receptor Ptc1 were more sensitive to experimentally-induced fibrosis (95). 
 
Notch Signaling 
Notch signaling, also first discovered in Drosophila, is initiated by binding of members 
for two ligand families, Jagged and Delta-like. Binding of ligands such as Jagged-1 (Jag-1) 
results in cleavage of Notch receptors by the γ-secretase complex and release of the active Notch 
intracellular domain (NICD) as illustrated in Figure 3 (96,97). Translocation of the NCID into 
the nucleus activates the transcription of numerous target genes such as the Hairy/Enhancer of 
Split (Hes) (98).  Abnormal Notch signaling participates in the pathogenesis of several human 
diseases including T-cell acute lymphoblastic leukemia and melanoma (99,100). Clinical trials 
with γ-secretase inhibitors already in progress in patients with T-cell acute lymphoblastic 
leukemia have yielded promising results (101). There is accumulating evidence for the 
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importance of Notch signaling in fibrotic diseases, although the molecular mechanisms involved 
in fibroblast activation and stimulation of ECM synthesis need clarification (102,103). 
Endothelin-1 
Endothelin-1 (ET-1) is a 21-amino acid polypeptide with potent vasoconstrictor activity 
that plays a crucial role in the pathophysiology of pulmonary arterial hypertension and has been 
identified as a prime therapeutic target for this disorder (104,105). A growing body of evidence 
has implicated ET-1 as a participant in organ fibrosis and numerous studies have described a 
variety of its profibrogenic activities. ET-1 has been shown to stimulate the synthesis of 
extracellular matrix macromolecules such as collagen types I and III and to inhibit the production 
of matrix degrading metalloproteinase-1 in cultured normal human fibroblasts (106,107). 
Furthermore, increased production of ET-1 has been demonstrated in a variety of human fibrotic 
diseases (108) and in experimentally induced pulmonary fibrosis (109) providing strong support 
to the concept that ET-1 also plays an important role in the pathophysiology of SSc, pulmonary 
fibrosis and other fibrotic diseases (110-112). ET-1 also was found to be involved in the 
induction of EMT (113). The role of ET-1 in EMT appears to be mediated through the 
endothelin A receptor (ET-A) via stimulation of endogenous TGF-β1 production (114).  
 
Strategies for Inhibition of Fibrosis 
Cellular phenotypic transitions resulting in myofibroblast formation. Recent delineation of 
the cellular phenotype transitions leading to the activated myofibroblast and the molecular 
identification of the pathways stimulating the fibrogenic processes have suggested new 
therapeutic approaches and targets. As discussed above and shown in Figure 1, there are four 
distinct potential cell sources of myofibroblasts. Three of these may be found as residents in the 
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affected tissue including fibroblasts, endothelial cells and epithelial cells. Thus blocking their 
transition into activated myofibroblasts could prevent the initiation of the fibrotic process itself. 
The most direct transition is the conversion of fibroblasts into myofibroblasts in which the 
activated cells express α-SMA and synthesize markedly increased amounts of ECM components. 
Undoubtedly, TGF-β is the most important causative agent involved in the fibroblast activation 
process as well as the mesenchymal transformation of epithelial and endothelial cells. Thus, 
preventing TGF-β action is clearly a potential therapeutic approach that may be achieved at 
several levels. 
 Interfering with TGF-β expression and activation. The complex signaling pathways 
initiated by TGF-β receptor binding offer multiple points of potential therapeutic intervention. 
TGF-β is constitutively synthesized and stored in an inactive form as a complex with specific 
binding proteins. Thus, the expression of TGF-β and the process of its release in an active form 
present therapeutic targets. Pirfenidone has been studied in experimental models of pulmonary 
fibrosis in which it suppressed TGF-β gene expression at the transcriptional level and 
significantly reduced the tissue levels of TGF-β mRNA and TGF-β in lavage fluid (115). 
Pirfenidone has been evaluated in four randomized, double-blind, placebo-controlled clinical 
trials. The collective results of these trials indicate that pirfenidone can reduce the rate of decline 
in lung function as measured by changes in forced vital capacity or total lung capacity but had 
little effect on diffusing capacity or resting arterial oxygen levels (116,117) 
 Several αv integrins can activate matrix-bound latent TGF-β and antibodies to the 
integrin αvβ6 expressed on epithelial cells blocked the activation of TGF-β preventing 
development of experimental lung fibrosis (118-120). Such a specific antibody approach has the 
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advantage of confining the blocking activity only to injury sites where αvβ6 is expressed only in 
epithelia and not compromise other important functions of TGF-β. 
 Angiotensin ll in certain circumstances exhibits remarkable profibrotic properties 
probably acting, at least in part, through stimulation of TGF-β production (121,122). Although 
angiotensin converting enzyme and AT1R inhibitors can block experimental models of lung 
fibrosis, there are no published reports regarding the use of these drugs in humans with 
pulmonary fibrosis. Therefore, it is still unclear whether ATll inhibition would have beneficial 
effects in fibrotic conditions, although the complex interactions between TGF-β and ATll 
suggest that pharmacologic inhibition of both systems may yield synergistic beneficial effects. 
 Blocking or inactivating extracellular TGF-β is a possible approach but results to date in 
humans have so far not been promising even though a TGFβ1 inhibitor peptide attenuated the 
progression of lung fibrosis in the bleomycin pulmonary fibrosis model (123). In a phase l/ll 
double-blind, placebo controlled trial of CAT-192, a human anti-TGFβ1 monoclonal antibody in 
patients with early diffuse SSc no improvement was found in the extent or severity of skin 
involvement or in lung function parameters (124). Also because of the wide-ranging functions of 
TGF-β, interfering globally with this essential signaling molecule could have untoward, toxic 
effects as was the case in the CAT-192 clinical trial (124). 
Inhibition of homing of circulating profibrotic cells. Circulating fibrocytes which 
express the CXCR4 receptor migrate to fibrotic sites in response to CXCL12 chemokine 
gradients and the CXCL12/CXCR4 axis appears to be up-regulated in SSc (125). CXCL12 
antagonizing antibodies as well as AMD3100, a CXCR4 antagonist significantly reduced 
bleomycin-induced lung fibrosis (126,127). AMD3100 is approved for the treatment of some 
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malignancies such as non-Hodgkin’s lymphoma, thus targeting the CXCL12/CXCR4 axis with 
available drugs represents a potentially effective anti-fibrotic therapeutic strategy. 
 Various experimental studies as well as ex vivo human data support a pro-inflammatory 
and pro-fibrotic role for the monocyte chemoattractant protein-1 (MCP-1/CCl-2). Inhibition of 
MCP-1 signaling by blocking its receptor, CCR2, reduced the accumulation of ECM proteins in 
animal models of skin and lung fibrosis (128).  Since antagonists of CCR2 are currently in 
clinical trials for various diseases, they may also be evaluated as anti-fibrotic agents.  
 
Blocking TGF-β signaling pathways (see Figure 2).  
 Inhibition of TGF-β receptor and canonical signaling.  There have been several 
studies of specific inhibitors of TGF-β type l receptor and the most thoroughly studied is SM305 
which proved to have excellent selectivity and potency against ALK5 and ALK4. In normal 
dermal fibroblasts, SM305 abrogated TGF-β-induced ECM gene expression, fibrogenic cytokine 
production, Smad3- and Smad2-dependent transcriptional responses, and fibroblast 
transdifferentiation into myofibroblasts (129). These inhibitory effects of SM305 were associated 
with potent selective suppression of TGF-β-induced phosphorylation and nuclear translocation of 
R-Smads. However, in unstimulated SSc fibroblasts, SM305 only caused variable and modest 
reduction in levels of type I collagen, and did not reverse constitutive Smad nuclear 
accumulation or the proportion of α-SMA-positive myofibroblasts. Together, these results 
indicate that ALK5-Smad signal transduction plays a fundamental role in mediating TGF-β-
dependent profibrotic responses in normal fibroblasts, whereas Smad nuclear accumulation in 
SSc fibroblasts appears to be ALK5 independent.  In light of its potent antifibrotic activities in 
normal dermal fibroblasts in vitro and in vivo, SM305-mediated ALK5 inhibition represents a 
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novel therapeutic strategy for controlling some TGF-β driven fibrotic conditions. The apparently 
contradictory results in SSc fibroblasts emphasize the complexity and heterogeneity of fibrotic 
reactions and the requirement to appropriately select therapeutic approaches to specific diseases. 
Specific inhibition of Smad3.   SIS3 is a potent and selective inhibitor of Smad3 that has 
been shown to block the phosphorylation of Smad3 induced by TGF-β without affecting the 
phosphorylation of Smad2 (130). SIS3 also inhibited the interaction of Smad3 with Smad4 as 
well as the stimulation of collagen production by TGF-β by normal fibroblasts and their 
transition to myofibroblasts. Significantly, SIS3 completely blocked the constitutive 
phosphorylation of Smad3 as well as the increased type I collagen expression in SSc fibroblasts. 
The effects of SIS3 on EndoMT and on experimentally-induced diabetic nephropathy were 
studied recently (131). EndoMT was induced in a mouse microvascular endothelial cell line 
(MMEC) through the use of advanced glycation end products (AGEs) and diabetic nephropathy 
was induced in mice by administration of streptozotocin (STZ) (124). SIS3 abrogated EndoMT 
in the MMEC, and reduced renal fibrosis and retarded progression of nephropathy in the STZ-
treated mice. Together, these studies suggest that SIS3 may prove to be an effective anti-fibrotic 
agent in selected diseases. 
 Selective inhibition of TGF-β non-canonical signaling pathways. A variety of targets 
present themselves when viewing the multiplicity of components encompassing the non-
canonical pathways initiated by TGF-β. Most prominent among these is the non-receptor 
tyrosine kinase, cAbl. The role of c-Abl in the fibrogenic process was serendipitously discovered 
when patients receiving treatment with imatinib mesylate (Gleevec) for chronic myelogenous 
leukemia (CML) caused by Bcr-Abl translocation had a remarkable reduction of bone marrow 
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fibrosis (132). Imatinib mesylate is a small molecule that specifically inhibits several tyrosine 
kinases including c-Abl, PDGFR, c-kit and c-fms by blocking the binding of ATP to the active 
kinase site. Imatinib mesylate has been shown to be effective in preventing the development of 
organ fibrosis in the kidney, lung, liver, and skin in several animal models (133-138). As seen in 
Figure 2 and 3, inactivating c-Abl blocks several downstream effector molecules required for the 
full TGF-β response, while simultaneous inhibition of PDGF potentiates its anti-fibrotic effect.  
 Imatinib has been used extensively and successfully in the treatment of CML and 
gastrointestinal stromal tumors with relatively little toxicity. However, the results in clinical 
trials of fibrotic diseases have been less clearcut. To date in five small clinical trials and several 
case reports a total of 108 patients with severe SSc have been treated with imatinib. Encouraging 
results were reported in 3 of 4 of these studies whereas the fifth study was prematurely 
terminated for safety reasons (139). In contrast, a recent trial of imatinib in patients with IPF 
failed to accomplish the primary outcome measures with little beneficial effect on survival or 
lung function improvement, possibly owing to the short term treatment period of only six months 
(140). However, in phase ll and lll clinical trials imatinib had a potent and prolonged beneficial 
effect on pulmonary arterial hypertension and reversed vascular remodeling even when already 
established (141). 
Second generation and wide spectrum tyrosine kinase inhibitors. A significant 
fraction of the patients treated in the imatinib anti-fibrotic trials withdrew because of mild to 
moderate side effects. Dasatinib and nilotinib are second-generation tyrosine kinase inhibitors 
with improved toxicity profiles that have proven effective in animal models of SSc and both of 
them require only nanomolar concentrations to obtain strong target inhibition compared to the 
micromolar concentrations required with imatinib (142). In addition to c-Abl and PDGFR, 
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dasatinib inhibits sarcoma-tyrosine (src) kinases which regulate c-Abl and are activated by TGF-
β and PDGF. A specific inhibitor of src kinases, SU6656, reduced skin fibrosis in experimental 
models of SSc (143).  However, no clinical data is currently available for either of these drugs.  
Nintedanib (BIBF 1120) is a potent intracellular inhibitor of tyrosine kinases that is in 
clinical development for the treatment of IPF and various cancers (144). Its targets include 
(PDGFR), vascular endothelial growth factor receptors (VEGFR), and fibroblast growth factor 
receptors (FGFR). Because signaling pathways activated by these tyrosine kinase receptors have 
been shown to be involved in lung fibrosis (145) and other fibrotic processes their inhibition may 
slow progression of IPF or liver fibrosis (146-149). In a rat model, such inhibition was shown to 
prevent the development of bleomycin-induced lung fibrosis when nintedanib was administered 
before or during the fibrotic phase of the disease (147). In a recently published clinical trial for 
IPF (150), nintedanib at the highest dose employed produced a significant improvement in the 
decline of forced vital capacity compared with the placebo group.  This dose also resulted in a 
lower incidence of acute exacerbations as compared with placebo with relatively mild and 
tolerable side effects. Given the intractable nature of IPF, these results suggest that wide 
spectrum tyrosine kinases may prove useful in treatment of fibrotic diseases. 
 
Rho-asssociated kinases  
 The intracellular mechanisms by which cytokines and growth factors such as TGF-β 
activate fibroblasts and stimulate ECM production are not completely understood. The small 
GTPase RhoA plays a central role in cell motility and adhesion through reorganization of the 
actin cytoskeleton. Activation of receptors switches RhoA from an inactive, GDP-bound 
conformation to an active GTP-bound conformation, which binds to and activates target 
20 
 
molecules (151). Cellular responses to RhoA are mediated by downstream Rho-associated 
kinases (ROCK) (152,153), which reorganize the actin cytoskeleton through phosphorylation of 
several substrates that contribute to the assembly of actin filaments and contractility, molecular 
events critical for the differentiation of resting fibroblasts into active myofibroblasts. When 
cultured fibroblasts were treated with TGF-β, inhibition of ROCK with the specific inhibitor 
Y27632 blocked the formation of myofibroblasts and reduced ECM production without cell 
toxicity (154). The MAP kinase ERK, identified as a down-stream target of ROCK in SSc 
fibroblasts, played a critical role in the profibrotic response to TGF-β treatment. It is not certain 
how ERK mediates its fibrotic effects, but it may regulate Smad3 signaling in certain cells or it 
may activate the transcription factor Sp1 which can stimulate transcription of the type I collagen 
genes and which is elevated in fibrotic conditions including SSc (155-158). Interestingly, two 
DNA intercalators, WP631 and mitoxantrone, have been shown to prevent binding of Sp1 to the 
COL1A1 promoter in human dermal fibroblasts. Both drugs inhibited basal COL1A1 production 
and mRNA levels without cytotoxicity or apoptosis and prevented TGF-β stimulation of 
expression (159). These data suggest that Sp1-DNA intercalators may be an effective approach 
for the treatment of fibrotic diseases. 
Inhibitors of hydroxymethylglutaryl-coenzyme A reductase such as statins, which are 
widely used to lower serum cholesterol, have been shown to have anti-fibrotic effects (160-162), 
which might be mediated by inhibition of ROCK. Statins interfere with the geranylgeranylation 
of membrane RhoA (163,164), which prevents the activation of RhoA, which in turn blocks the 
activation of Rock. Furthermore, a specific inhibitor of geranylgeranyl transferase 1 inhibited 
type I collagen gene expression in normal and SSc fibroblasts (165). Thus, the antifibrotic 
activity of statins supports the antifibrotic effects of ROCK inhibitors. The ROCK inhibitor, 
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fasudil, has been used in Japan and China for the treatment of coronary and cerebral artery 
vasospasm (166,167). Considering the very low rate of side effects and the favorable clinical 
experience in those studies, ROCK inhibitors should be considered as promising candidates for 
targeted anti-fibrotic therapy.  
 
Caveolin-1  
 Caveolin-1, the most important structural component of caveolae, is also found in several 
other cellular sites and is expressed in a variety of cell types including epithelial cells, 
endothelial cells and fibroblasts. Of interest in the present context is its potential role in 
regulation of the fibrotic reaction and prominent in this regard is its ability to bind and inhibit a 
substantial number of kinases (168). High levels of caveolin-1 are found in normal lung 
fibroblasts, whereas much lower levels are found in lung fibroblasts from fibrotic lungs of SSc 
and IPF patients (169-171).  This reduction in caveolin-1 is associated with increased activity of 
several signaling kinases (MEK, ERK, JNK, Akt) and increased expression of matrix molecules. 
An interesting finding is the localization in caveolin-1 of the binding site which functions as a 
kinase inhibitor (amino acids 82-101) known as caveolin-1 scaffolding domain (CSD). When 
fused to the C terminus of the Antennapedia internalization sequence, CSD can enter cells with 
low caveolin- concentrations where, like the intact molecule, it can bind kinases, inhibit their 
activity and also inhibit collagen expression (171). In caveolin-1 null mice, alveolar walls are 
thickened, the diameter of alveolar spaces is reduced, and ECM is significantly increased (172-
174). In the bleomycin lung fibrosis model caveolin-1 levels are depressed, and systemic 
administration of CSD blocks the fibrotic process (170), suggesting a causal relationship 
between low caveolin-1 levels and lung fibrosis. 
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TGF-β and caveolin-1 signaling interact in several ways. TGF-β inhibits caveolin-1 
expression in several types of cells including lung and dermal fibroblasts, while caveolin-1 
modifies TGF-β signaling by inhibiting Smad3 phosphorylation and its translocation to the 
nucleus (175). Caveolin-1 also regulates TGF-β signaling through its effects on the endocytosis 
of TGF-β ligand-receptor complexes, which are present in both caveolin-1 rich lipid rafts and 
clathrin-rich early endosomes (176,177).  Early endosomal internalization increases TGF-β 
signaling while caveolin-1-rich lipid raft internalization leads to receptor degradation and 
inhibition of TGF-β signaling (176). Thus, the loss of caveolin-1 in fibrotic tissues will promote 
TGF-β signaling by early endosomal internalization. 
 The above discussion must be viewed with some caution, however, since other reports 
have found higher levels of caveolin-1 in some SSc dermal fibroblasts than in normal dermal 
fibroblasts and found that caveolin-1 overproduction enhanced collagen expression while 
caveolin-1 depletion inhibited collagen expression (178,179). Furthermore, caveolin-1 was found 
to be a positive regulator of phospho-Smad1 and CTGF, a powerful profibrotic cyokine (178). 
 In spite of these caveats, the use of CSD as a molecular therapeutic must be considered 
for treating certain fibrotic conditions, such as in the lung, because caveolin-1 regulates several 
signaling pathways which may be a more effective approach than use of agents targeting a single 
specific pathway. 
 
Transcription and other intracellular factor modulation  
The c-Abl/PKCδ/Fli-1 pathway. As discussed above, c-Abl has a critical role in 
mediating the fibrotic response intiated by TGF-β. An important part of this activity is the 
phosphorylation/activation and nuclear localization of PKCδ. PKCδ then phosphorylates the 
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transcriptional repressor Fli1 at threonine 312 which promotes its interaction with p300/CREB-
binding protein-associated factor and subsequent acetylation. These molecular events cause Fli-1 
dissociation from the human α2(I) collagen gene promoter, resulting in enhanced transcription of 
the gene (see Figure 2) (180). A breakthrough study on the role of PKCδ in the regulation of 
collagen gene expression found that selective inhibition of PKCδ markedly decreased the 
production of collagen by SSc fibroblasts (181,182) and a very specific peptide inhibitor of 
PKCδ is now being investigated as a protective agent for reperfusion injury after myocardial 
infarction (183). Previous extensive animal experiments have shown this peptide to be a highly 
effective and specific inhibitor of PKCδ with minimal toxic effects, suggesting its potential 
utility in fibrotic disorders. 
The AP-1 transcription factor family. The transcription factor AP-1 is a heterodimeric 
molecule composed of members of the Jun (c-jun, junB and junD) and the Fos family (cFos, 
FosB, Fra-1 and Fra-2).  Currently, the most important of these with respect to fibrotic conditions 
are c-Jun, JunD, cFos, and Fra-2. TGF-β stimulated the expression of Fra-2 in dermal fibroblasts 
through ERK signaling and JunD through Smad3 pathway (184). JunD, cJun and cFos were 
found to be overexpressed in the skin and dermal fibroblasts of SSc patients (185). Interestingly, 
the effects of AP-1 on collagen synthesis seem not to be restricted to SSc dermal fibroblasts but 
might also occur in cardiac, renal, and keloid fibroblasts (186-188). These are important findings 
since they suggest that a critical mode of TGF-β profibrotic activity is through up-regulation of 
AP-1 and its resultant transcriptional activity. In this regard it should be noted that AP-1 up-
regulates tissue inhibitor of metalloproteinases (TIMP) while decreasing matrix 
metalloproteinase-1 (MMP-1) (189). Thus, AP-1 not only increases the production of matrix 
components, but also inhibits their degradation resulting in their net accumulation. 
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T-5224 is a small molecule inhibitor of AP-1 that was developed based on the x-ray 
crystal structure of the basic region leucine zipper domain of the AP-1–specific DNA complex 
composed of c-Jun/c-Fos. In a preclinical animal study, T-5224 had an excellent safety profile 
(190). T-5224 blocked the in vitro effects of TGF-β on the differentiation of resting fibroblasts 
into myofibroblasts and stimulation of ECM production and in vivo prevented dermal fibrosis 
induced by bleomycin (185). Because of the potent antifibrotic effects and the favorable safety 
profile of T-5224, inhibition of AP-1 signaling by T-5224 and other similar potential agents must 
assume a high priority for the treatment of fibrotic diseases in well-controlled clinical test 
settings. 
In contrast to the pathways used in the up-regulation of expression of c-Jun by TGF-β 
and PDGF, activation of c-Jun by phosphorylation proceeds through the activity of c-Jun N-
terminal kinase (JNK). The selective JNK inhibitor, CC-930, prevented the phosphorylation of 
cJun, reduced the stimulatory effects of TGF-β and PDGF on collagen production, prevented 
collagen accumulation and dermal thickening in bleomycin and Tsk-1 mice experimental fibrotic 
models, and, highly remarkably, it induced regression of established experimental fibrosis (191). 
Phase III clinical trials with various inhibitors of JNK for the treatment of rheumatoid arthritis 
and different types of cancer showed that inhibition of JNK is well tolerated in humans (192). 
Mice treated with CC-930 did not show any signs of toxicity and initial results from dosing 
studies in healthy human volunteers have indicated that CC-930 is well tolerated (193). Thus, 
JNK is a viable target for treatment of fibrotic diseases.  
 
 JAK2 and Stat3. Janus kinases (JAKs) are receptor-associated tyrosine kinases with 
central roles in cytokine- and growth factor signaling. Upon cytokine binding to the receptor, 
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JAK kinases become activated and phosphorylate tyrosine residues in the cytoplasmic region of 
the receptor (194). STATs (Signal Transducer and Activator of Transcription) are latent 
cytoplasmic transcription factors that are recruited to these phosphorylated receptor sites and 
become activated by phosphorylation by JAKs of a conserved tyrosine residue near the C-
terminus after recruitment to an activated receptor complex. Activated STATs then dimerize and 
translocate into the nucleus where they activate transcription of several target genes (194). JAK2 
is a key-regulator of cytokine signaling and alterations of JAK2 signaling cause profound 
changes in response to cytokine stimulation. Point mutations in the JAK2 gene, which result in 
constitutive activation of JAK2, are critical in the pathogenesis of myeloproliferative diseases 
(194,195) and this critical role has stimulated the development of JAK2 inhibitors, several of 
which are currently being evaluated in clinical trials with promising results (196). 
 Increased activation of JAK2 and STAT3 were detected in the skin of SSc patients, 
which persisted in cultured SSc fibroblasts (197). The selective JAK2 inhibitor, TG 101209, 
reduced basal collagen synthesis in SSc fibroblasts and prevented the stimulatory effects of 
TGFβ on fibroblasts. Treatment with TG 101209 not only prevented bleomycin-induced fibrosis, 
but also effectively reduced skin fibrosis in the Tsk-1 mice animal model of tissue fibrosis (197).  
JAK2 may not only act as a downstream mediator of TGF-β but may also amplify TGF-β 
signaling by stimulating the expression of TGF-β since incubation with TG 101209 caused a 
dose-dependent decrease in the mRNA levels of TGF-β in SSc fibroblasts. Furthermore, other 
studies demonstrated that inhibition of STAT3 and overexpression of suppressor of cytokine 
signaling 1 (SOCS1) reduced the expression of TGF-β (198,199). Considering that several 
pharmacological inhibitors of JAK2 are available and appear to be well tolerated, targeting JAK2 
for the treatment of fibrotic diseases deserves careful consideration. 
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Peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ is a nuclear 
receptor originally identified in adipose tissue but is broadly expressed and plays a crucial role in 
glucose and lipid metabolism. Recent studies have described new functions for PPARγ in the 
regulation of connective tissue homeostasis. A decrease in PPARγ expression accompanied 
progression of fibrosis in experimental models of lung, liver and kidney fibrosis and was a 
consistent finding in skin and lung tissues from SSc patients (200). In addition, adiponectin 
levels, a sensitive and specific index of PPARγ activity, were reduced in the serum of patients 
with diffuse cutaneous SSc and correlated inversely with the extent and severity of skin sclerosis 
(201). Thus, adiponectin might have potential as a biomarker in SSc. Several profibrotic factors 
such as TGF-β, Wnt proteins and IL-13 suppress PPARγ activity or expression (202). Treatment 
of normal fibroblasts with the endogenous PPARγ prostanoid ligand, 15d-prostaglandin J2, or 
with the PPARγ pharmacologic agonist, rosiglitazone, abrogated TGF-β induced fibrotic 
responses (203-205). In addition, PPARγ blocks EMT and the differentiation of preadipocytes 
into fibroblasts (206), a putative novel mechanism of tissue fibrosis. Since rosiglitazone is 
already used in the treatment of diabetes mellitus, evaluation of it as an anti-fibrotic agent in 
clinical trials appears warranted.  
 
Inhibition of other profibrotic signaling pathways  
Wnt signaling. TGF-β appears to be the major factor activating the canonical Wnt pathway in 
fibrotic diseases probably mediated largely by a decrease of Dkk-1 and although other molecular 
mechanisms are possible, the addition of recombinant Dkk-1 blocked the stimulatory effects of 
TGF-β on the canonical Wnt pathway in fibroblasts (207). Wnt signaling caused the transition of 
resting fibroblasts into activated myofibroblasts, and increased the production of ECM 
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components. Dkk-1 is currently being investigated as a potential therapeutic target in other 
diseases and the cumulative data suggest that inhibition of the canonical Wnt pathway might be 
an effective approach to target TGF-β signaling in fibrotic diseases 
Hedgehog signaling. Abnormal stimulation of Hh signaling might be driven by several factors. 
Hypoxia at levels similar to those observed in skin of SSc patients induces the expression of Shh 
(208,209). However, a more likely general scenario is that profibrotic cytokines including TGF-
β, PDGF, and Wnt drive Shh overexpression (210-212). It has been shown that Shh stimulated 
resting fibroblasts to differentiate into myofibroblasts and that overexpression of Shh in mice 
caused accumulation of collagen and dermal thickening (213). Thus, Hh signaling might play a 
central role in the pathogenesis of fibrosis. Both Smo-specific siRNA or the small-molecule 
inhibitor LDE223, a highly selective antagonist of the Hh coreceptor Smo effectively blocked the 
aberrant activation of the hedgehog pathway while LDE223 prevented bleomycin-induced 
dermal fibrosis (214). In addition, treatment of Tsk-1 mice with LDE223 prevented progression 
of fibrosis and induced its regression (214). Several small molecule inhibitors of Smo including 
LDE223 are currently being evaluated in clinical anti-cancer trials with minimal side effects 
reported so far. Thus, pharmacologic inhibition of the Hh pathway might be a promising 
approach to treatment of fibrotic disorders as illustrated in Figure 3.  
Notch signaling. Recent studies in SSc skin suggest that infiltrating T cells expressing the Jag-1 
ligand might activate Notch signaling in fibroblasts leading to their transition to myofibroblasts 
with increased expression of ECM (102,103). Although Notch signaling may be induced under 
hypoxic conditions or by TGF-β, the detailed molecular mechanisms responsible for this 
transition remain to be determined (215-217). Such activation of Notch signaling has also been 
found in mouse models of dermal fibrosis (218). Treatment with the γ-secretase inhibitor DAPT, 
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which blocks Notch signaling, significantly decreased experimental pulmonary and dermal 
fibrosis in mice and in SSc dermal fibroblasts (102,219). Since various inhibitors of γ-secretase 
are in clinical trials for different types of malignancies, similar trials in fibrotic diseases appear 
both feasible and warranted. 
Other important pathogenetic mechanisms in fibrotic diseases 
Role of micro RNAs in Fibrosis. MicroRNAs (miRNAs) are small (~22 nucleotides), 
evolutionarily conserved non-coding RNA which modulate the expression of protein coding 
genes at the post-transcriptional level by binding complementarily to the 3’ untranslated region 
(UTR) of target mRNAs and suppress expression by either inhibiting mRNA translation or 
facilitating mRNA degradation (220). Approximately 1400 miRNAs have been identified to date 
in humans with most miRNA genes being located in introns, exons and UTRs of protein coding 
genes (221). Although the role of miRNA in cancer has been extensively studied, recent interest 
has been devoted to elucidating their participation in tissue fibrosis and fibrotic diseases (222). 
Several miRNA, including let-7, miR-21, mir-29 and miR-155 are regulated by TGF-β and  their 
targets are mRNAs coded by genes involved in matrix homeostasis such as those encoding 
collagens, matrix metalloproteinases, and Smad signaling proteins. miR-29 and let-7 are 
antifibrotic (223) whereas miR-21 and miR-155 are profibrotic and their expression is increased 
in fibrotic reactions (224). Conversely, miR-29 was found to be markedly down-regulated in SSc 
dermal fibroblasts and skin (225). Overexpression of miR-29 in SSc fibroblasts decreased the 
levels of type 1 and type lll collagens demonstrating a direct effect of miR-29. Similar reduction 
of miR-29 was observed in fibrotic reactions in other organs, including heart, kidney and lung. 
TGF-β, PDGF-B or IL-4 reduced the levels of miR-29 in normal fibroblasts to levels similar to 
29 
 
those observed in SSc fibroblasts and a marked reduction was also seen in the bleomycin model 
of skin fibrosis (225). Although hypothetically regulation of miRNA expression could be 
therapeutically exploited, presently there are considerable practical barriers to its 
implementation.  
The Immune Response and Fibrotic Reactions. In many instances, a persistent inflammatory 
reaction characterized by accumulation of immune cells including various lymphocyte 
populations and macrophages and the  release of growth factors and cytokines by these cells lead 
to activation of myofibroblasts and a fibrotic response. Owing to space limitations and to the 
availability of several outstanding recent reviews covering the immunologic and inflammatory 
aspects of tissue fibrosis (226,227), the present discussion will be confined to a brief review of 
the direct involvement of the immune response in promoting or inhibiting fibrogenesis. Of 
singular importance in this regard is the role of Toll-like receptors (TLRs) which are activated 
not only by microbial ligands termed pathogen-associated molecular patterns (PAMPs) which 
are specifically recognized by TLRs, but also a variety of ligands derived from host components 
collectively referred to as damage-associated molecular patterns (DAMPs) as well as nucleic 
acid-containing immune complexes (228). TLRs are found not only in cells of the immune 
system but also in fibroblasts. Type I interferon production, linked to innate immune signaling 
through TLRs, can result in TLR3-mediated responses in normal skin fibroblasts (229). While 
TLR3 is an endosomal receptor, TLR4 is expressed on the fibroblast cell surface and can 
recognize various DAMPs. Although activation of TLR4 induces a modest fibrotic reaction by 
itself, it stimulates a synergistic response in association with TGF-β (230). Thus, fibroblast 
innate immune signaling might be a critical contributor to the perpetuation of a profibrotic 
response.  
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 The adaptive immune response is complex in that it contributes both profibrotic and 
antifibrotic aspects. The TH2 profibrotic responses, are characterized most importantly by the 
production of IL-13, which has been shown to be a potent stimulator of fibroblast proliferation 
and collagen production and when overexpressed induced skin and lung fibrosis in various 
experimental models (231). Elevated levels of IL-13 have been found in patients with SSc and it 
has been implicated in the pathogenesis of IPF, experimental lung fibrosis, SSc, and liver fibrosis 
(232-234). A recent study demonstrated that IL-13 signaling via IL-13Ra(2) activated AP1 
which then stimulated the transcriptional activity of the TGF-β promoter. In contrast, the 
inhibition of IL-13 signaling reduced the production of TGF-β and markedly reduced collagen 
deposition in bleomycin-induced pulmonary fibrosis (235). There are two phase II, double-blind 
placebo, randomised-controlled trials currently ongoing in SSc-ILD and IPF in which a fully 
humanized monoclonal antibody against human IL-13 is being tested. 
 TH1 effector T cells, as well as natural killer and natural killer T cells, produce IFN-γ 
which inhibits fibrosis, at least in part, by antagonizing the activity of TGF-β. IFN-γ inhibits the 
phosphorylation of Smad3 as well as inducing the expression of inhibitory Smad7 (236-238). 
IFN-γ also blocks the TH2 cytokine-induced differentiation of peripheral blood monocytes into 
fibrocytes (239). In spite of this supporting evidence, clinical studies testing the therapeutic 
potential of IFN-γ in IPF, SSc and other fibrotic disorders have been mostly disappointing (240).  
 IL-17A, expressed by TH17 cells, has been implicated in the pathogenesis of pulmonary, 
cardiac and hepatic fibrosis (241-243). The proinflammatory cytokines IL-1β and IL-23 have 
been identified as initiators of TH17 responses and it has been found that in some circumstances 
TGF-β may partially exert its fibrotic effects through IL-17A production (241,244). Extracellular 
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bacteria and certain fungi can lead to inflammasome activation and IL-6 production, which in the 
presence of TGF-β1, can drive TH17 differentiation (226). Il-6 has been reported to be up-
regulated in the serum, dermal fibroblasts and peripheral blood mononuclear cells of SSc 
patients, and found to correlate with the extent of skin fibrosis (245). Blocking of IL-6 in vitro 
decreased collagen production, and IL-6 deficiency attenuated lung fibrosis in the bleomycin 
model (246). Tocilizumab, a humanized monoclonal antibody directed against the IL-6 receptor, 
has been approved for the treatment of RA. Although preliminary data in a small number of 
patients from one study on the effects of tocilizumab on polyarthritis in SSc patients did not 
show any change in the extent of cutaneous involvement over a 6-month period (247), there is a 
currently ongoing trial to examine the effects of tocilizumab in diffuse SSc. 
Role of Reactive Oxygen Species (ROS) in Fibrotic Diseases 
 Numerous studies have provided compelling evidence for the involvement of ROS in the 
development of tissue fibrosis (248-250). Although ROS are produced under physiological 
conditions and are essential for many intracellular reactions including fibroblast proliferation, 
there is evidence that SSc fibroblasts produce ROS constitutively and that elevated ROS levels 
may be involved in the increased collagen expression in these cells (251). In addition increased 
urinary 8-oxodG levels in SSc patients suggest marked oxidative stress (252). Although several 
classes of enzymes can produce ROS, in the present context the most important is the NADPH 
oxidase (NOX) family of oxidoreductases, especially NOX4 which is the most widely distributed 
isoform. NOX4 is one of seven NADPH isoforms and like the others its structure consists mainly 
of a six-transmembrane domain known as the gp91phox domain (253,254). Despite their 
extensive similarity in structure and enzymatic function, members of the NOX family differ in 
their mechanism of activation. In particular, NOX4 requires interaction with a second 
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membrane-bound subunit, p22 phox, and in contrast with other members of the NOX family 
does not require other subunits (255). NOX4 generates predominantly hydrogen peroxide (H2O2) 
rather than superoxide (O2
-) (256,257), although it is able to generate superoxide under specific 
conditions. 
 Because of the increasing interest in the potential role of ROS in fibrogenic processes in a 
variety of tissues and the realization that NOX family members are key effectors, substantial 
efforts are now being devoted to develop selective NOX inhibitors. The first of these to be 
obtained are the triazolo pyrimidines such as VAS2870 and VAS3947, which inhibit NOX 
specifically but are not isotype selective (258). These compounds have been shown to be 
effective in vitro in several cell systems expressing different NOX isotypes. However, because of 
the lack of isotype specificity, intense efforts have been devoted to the development of NOX4-
specific or selective inhibitors (259). To date the best of these are pyrazolopyridine dione 
derivatives, the most potent of which is GKT136901. This and similar compounds demonstrated 
good oral bioavailability and safety profiles as well as dual inhibitory activity for NOX4 and 
NOX1 in the nanomolar range and have been shown to inhibit EMT and prevent bleomycin-
induced pulmonary fibrosis. These findings suggest that the best pyrazolopyridine dione 
derivatives warrant clinical trials for treatment of IPF and other fibrotic disorders. 
Matrix Stiffness and Fibrogenesis. Recent studies have convincingly demonstrated that the 
mechanical properties of the ECM can modulate the behavior of resident cells including 
regulation  of their proliferation, biosynthetic activities and  stage of differentiation, although the 
molecular mechanisms mediating these activities are only beginning to be understood. When 
lung fibroblasts were cutured on polyacrylamide substrates of varying stiffness, they responded 
by producing increasing amounts of polymerized α-SMA (260,261). This actin polymerization 
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resulted in nuclear translocation of MKL1, a cofactor that plays a central role in expression of 
fibrotic genes including α-SMA. Furthermore matrix stiffening promoted production and 
activation of RhoA, increased ROCK activity and enhanced fibroblast contractility. Inhibition of 
RhoA/ROCK blocked these responses including MKL1 nuclear translocation and myofibroblast 
differentiation. Similar results were obtained with hepatic stellate cells which became 
progressively myofibroblastic with increasing substrate stiffness (262).  
 These experiments suggest that as fibrogenesis proceeds and tissues become increasingly 
stiff, a vicious cycle can be initiated in which the stiffness itself can promote further ECM 
production. Furthermore, these findings suggest that therapeutic approaches aimed at the 
reduction of tissue stiffness may prove to be extremely potent antifibrotic agents. As discussed 
above, RhoA/ROCK inhibitors including statins are already available and may be more generally 
useful as anti-fibrotic drugs than currently understood. A substantial portion of ECM stiffness 
can be attributed to the crosslinking of collagen mediated by the copper-requiring enzyme lysyl 
oxidase, rendering controlled inhibition of lysyl oxidase a potential therapeutic approach. In this 
regard it should also be pointed out that the drug d-penicillamine, which was extensively utilized 
as an antifibrotic agent in the past (263-266) but was discredited following a high dose versus 
low dose comparative study (267), is a potent inhibitor of collagen crosslinking  and may, 
therefore, be extremely effective in reducing tissue stiffness. These considerations should lead to 
the re-evaluation of d-penicillamine as an antifibrotic agent. Another potential approach to the 
fibrotic stiffness problem in carefully selected cases is the direct injection of clostridial 
collagenase into the affected tissue. This technique has been used successfully in nonsurgical 
treatment of Dupuytren’s contracture (268). 
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Inhibition of Fibrosis by an Endostatin-1 Derived peptide. A recent novel and potentially 
ground-breaking study has shown that a cell-permeable peptide corresponding to the carboxy 
terminal end of the endostatin-1 molecule is capable of exerting remarkable effects on the pattern 
of gene expression of human normal fibroblasts in culture (269). The peptide caused a potent 
antifibrotic effect modulating several aspects of fibroblast biology including a decrease in 
expression of the important profibrotic transcription factor EGR-1, reduction of the expression of 
type I collagen and fibronectin, and inhibition of the expression of lysyl oxidase, the main 
collagen crosslinking enzyme. This study opens up the possibility of utilizing cell-permeable 
peptides for the treatment of SSc, IPF, and other fibrotic diseases. 
 
Discussion and Conclusions 
 The present challenges facing the field of fibrotic diseases in terms of therapy bear some 
similarities to the approach for cancer treatment. The treating physicians are confronted with 
complex pathogenetic processes which, although similar in their final outcome, are quite diverse 
in specific molecular mechanisms. Thus, identifying critical targets and appropriate, effective 
therapies is extremely difficult. Owing to the diversity and heterogeneity of the fibrotic diseases 
with respect to their etiology and pathogenesis, novel screening approaches will be required to 
characterize and identify particular pathways operative in individual cases.  Substantial progress 
in this direction has been made in the cancer field, mainly due to the availability of large data 
bases documenting genetic alterations in malignant cells. While this approach has at best a 
limited place in fibrotic disease, RNA microarray screening of samples derived from affected 
tissues is feasible and is currently being implemented. Such analyses have been carried out 
comparing samples from fibrotic tissue from SSc and IPF patients and control tissues in which 
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substantial differences were observed between the normal and fibrotic samples. However, based 
upon this kind of data it has not been possible, as yet, to develop pathogenetic models which 
could lead to rational therapeutic approaches. As detailed in the text, there has been an explosive 
growth in new findings documenting alterations in potentially profibrotic growth 
factors/cytokines and in their signaling pathways. The challenge is how to apply these findings in 
individual cases. Presently, the only way to determine such changes is by invasive biopsies and 
even then sophisticated screening and molecular analyses of the samples would be difficult at 
best or marginally informative. Thus, there is an urgent need for the identification of novel 
biomarkers, most desirably from serum or plasma samples, which have the power to categorize 
fibrotic reactions with respect to the active pathogenetic mechanisms and pathways. 
 A second major difficulty is the lack of suitable surrogate parameters capable of 
measuring the effectiveness of novel therapeutic agents. As listed in Table I (and this list is by no 
means complete) there is a plethora of drugs which are attractive candidates based largely on in 
vitro evidence from laboratory studies and supportive animal experimental findings, although 
they have not been appropriately tested in controlled clinical studies. Constructing well designed 
controlled clinical trials will be a difficult although a quite necessary step that will require the 
cooperation of multiple investigators and centers using both non-invasive and invasive 
measurements as discussed recently for SSc clinical trials (270). On the positive side, many 
existing drugs have been approved for other purposes (e.g. imatinib, rosiglitozone) eliminating 
the necessity for extensive safety testing. Another feature that is now becoming apparent and that 
fibrotic diseases share with cancer is the necessity of using multiple drugs to affect different 
pathways. This is due to the fact that the pathogenetic mechanisms of fibrotic diseases consist of 
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complex networks of multiple and often redundant pathways and blocking a single node, while 
occasionally effective, will usually not be sufficient or effective.  
However, it is expected that in the near future translational medicine will be able to 
successfully overcome these serious challenges and convert the extensive knowledge acquired 
recently about the cellular and molecular mechanisms of tissue fibrosis into effective therapeutic 
approaches for the devastating and currently incurable fibrotic diseases. 
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FIGURE LEGENDS 
Figure 1. Cellular origins and pathways leading to activated myofibroblasts. Insults caused 
by a variety of putative causative agents such as bacteria, toxins, ROS, or radiation in genetically 
predisposed hosts result in inflammation. Activated inflammatory cells secrete cytokines and 
growth factors such as TGF-β which cause fibroblast activation and differentiation of endothelial 
and epithelial cells into myofibroblasts. These cells produce excess amounts of ECM resulting in 
dysfunctional fibrotic tissue. 
Figure 2. TGF-β signaling pathways critical for the fibrotic response. Illustrated are 
canonical and non-canonical pathways originating from two representative dimeric receptors. 
Following TGF-β binding, the TGFβRll receptor recruits a TGFβRl, either activin-like kinase-1 
or activin-like kinase-5 and activates it by phosphorylaton. Activin-like kinase 5 (Alk 5) then 
specifically phosphorylates receptor-regulated Smad2 and Smad3 which then complex with Co-
Smad4 resulting in their transport to the nucleus where they interact with various co-activators or 
co-repressors to regulate transcription of critical genes, here represented by connective tissue 
growth factor (CTGF) and α1(l) and α2(1) collagen genes. Also illustrated are several non-
canonical pathways. An important one involves the phosphorylation and activation of the cellular 
Abelson non-receptor kinase (c-Abl) resulting in activation of several downstream critical factors 
including Smad1, early growth response protein (EgR) and protein kinase C delta (PKC-δ), all of 
which contribute to the fibrotic response.  
Figure 3. Growth factor/cytokine signaling pathways important in fibrogenesis. Illustrated 
are the signaling pathways for platelet derived growth factor (PDGF), Notch, Wnt and 
Hedgehog. Each of these pathways is activated by ligand-binding to specific receptors, but the 
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subsequent signaling transmission mechanisms between these pathways differ dramatically (see 
text). For clarity of presentation they have been abbreviated with only the essential features 
presented. 
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TABLE 1.  ANTI-FIBROTIC THERAPEUTIC TARGETS AND PHARMACOLOGIC 
AGENTS 
 
   Target         Agent 
TGF-β expression and activation   pirfenidone 
       αvβ6 antibody 
       ATI and ATII receptor blockers  
       ACE inhibitors 
       CAT-192 (anti-TGF-β1 monoclonal AB) 
       Caveolin scaffolding domain (CSD) 
TGF-β Signaling pathways 
   Canonical 
TBR1      SM305 
 SMAD3     SIS3 
 
   Non-canonical 
 
c-Abl      imatinib mesylate 
 PDGFR     dasatinib 
 c-kit      nilotinib 
PKC-δ small specific polypeptide  
       rottlerin derivatives 
 
CTGF       monoclonal CTGF antibodies 
Inhibition of fibrocyte homing 
 
CXCL12     antibody 
CXCR4     AMD3100 and others 
CCR2      inhibitors (PF-04136309) 
 
src       dasatinib, SU6656 
VEGFR      nintedanib (BIBF1120) 
FGFR       sorafenib 
Other intracellular pathways 
JAK2      TG 101209 
Wnt      Dkk-1 
Hedgehog     LDE223 
Notch      DAPT 
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RhoA      statins,  
GGT inhibitor 
ROCK      Y27632, fasudil 
MEK, ERK,JNK, Akt,   caveolin scaffolding domain (CSD) 
JNK      CC-930 
 
Transcription factors 
AP-1      T-5524 
Fli-1      macrolide antibiotics 
Sp1      intercalating agents 
PPARγ     rosiglitazone 
 
Other mechanisms 
IL-13      humanized monoclonal AB 
IL-6 receptor     Tocilizumab 
TLR      TLR inhibitors (E5564, TAK-242) 
Nox4 (ROS)     GKT136901 
 ET-1      Bosentan, other ET receptor blockers 
Matrix stiffness, collagen crosslinking d-penicillamine, Clostridial collagenase 
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